+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Fatal Pseudomona pneumonia following rituximab therapy in a patient with epidermolysis bullosa acquisita



Fatal Pseudomona pneumonia following rituximab therapy in a patient with epidermolysis bullosa acquisita



Journal of the European Academy of Dermatology and Venereology 21(8): 1141-1142




(PDF emailed within 0-6 h: $19.90)

Accession: 053213478

Download citation: RISBibTeXText

PMID: 17714160

DOI: 10.1111/j.1468-3083.2006.02127.x



Related references

A Case Report of the Use of Rituximab and the Epidermolysis Bullosa Disease Activity Scoring Index (EBDASI) in a Patient with Epidermolysis Bullosa Acquisita with Extensive Esophageal Involvement. Acta Dermatovenerologica Croatica 26(4): 325-328, 2019

Successful treatment of epidermolysis bullosa acquisita with rituximab therapy. Journal of Dermatology 39(5): 477-479, 2012

A case of recalcitrant epidermolysis bullosa acquisita responsive to rituximab therapy. Pediatric Dermatology 31(2): 241-244, 2015

A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. British Journal of Dermatology 156(1): 194-196, 2007

Long-term results of rituximab-intravenous immunoglobulin combination therapy in patients with epidermolysis bullosa acquisita resistant to conventional therapy. Journal of Dermatological Treatment (): 1-5, 2016

Refractory epidermolysis bullosa acquisita: successful treatment with rituximab. Clinical and Experimental Dermatology 34(8): E979-E980, 2010

Subcutaneous immunoglobulin therapy for immunomodulation in a patient with severe epidermolysis bullosa acquisita. Clinical Immunology 129(3): 518-519, 2008

Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab. British Journal of Dermatology 157(2): 417-419, 2007

The use of rituximab in treatment of epidermolysis bullosa acquisita: Three new cases and a review of the literature. Dermatologic Therapy 31(6): E12726-E12726, 2018

Successful use of combined corticosteroids and rituximab in the treatment of recalcitrant epidermolysis bullosa acquisita. Annales de Dermatologie et de Venereologie 136(11): 795-799, 2010

Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Archives of Dermatology 142(2): 147-150, 2006

Premonitory epidermolysis bullosa acquisita mimicking eyelid dermatitis: successful treatment with rituximab and protein A immunoapheresis. American Journal of Clinical Dermatology 11(4): 289-293, 2010

Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab. Dermatology 215(3): 252-255, 2007

Fatal vascular involvement in systemic lupus erythematosus following epidermolysis bullosa acquisita. Acta Dermato-Venereologica 75(2): 143-146, 1995

Absence of platelet aggregation activity in blister fluids from epidermolysis bullosa dystrophica and epidermolysis bullosa acquisita. Journal of Dermatological Science 1(6): 467-468, 1990